Due to the advent of FLT3 targeted therapy for AML patients in 2017 with the approval of midostaurin [12], we aimed to uncover the pathophysiological role of FLT3 in BP progression and reevaluate the use of FLT3 inhibitors for CML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.